Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on September 11, 2023, regarding events occurring on September 5, 2023. The filing primarily addresses significant changes in executive leadership, specifically the appointment of a new Chief Medical Officer (CMO) and the departure of the previous CMO.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- Base Salary (New CMO): $415,000 per year.
- Target Annual Bonus: 40% of base salary.
- Inducement Equity Grants: 75,000 stock options and 54,700 restricted stock units (RSUs).
- Option Exercise Price: $0.6897 per share.
Material Changes
The primary material change reported is the transition of the Chief Medical Officer role:
- Appointment: Mitchell Jones, M.D., Ph.D., was appointed Chief Medical Officer effective September 5, 2023.
- Departure: Herbert Slade, MD, FAAAI, ceased serving as Chief Medical Officer on September 5, 2023, and will transition to a consulting role.
- Unregistered Sale of Equity: The company issued inducement grants to Dr. Jones exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D.
Outlook, Risks, and Management Commentary
Management Commentary: The filing highlights Dr. Jones' extensive background, including over 16 years of experience in translational and clinical activities for therapeutic candidates in inflammatory bowel disease, metabolic disease, and oncology. His prior roles include VP positions at Chemomab, Finch Therapeutics Group, and Biora Therapeutics.
Compensation Structure and Risks:
- Severance: In the event of termination without "Cause" or resignation for "Good Reason," Dr. Jones is eligible for 9 months of base salary and COBRA benefits.
- Change in Control: If termination occurs within the "Change in Control Period" (3 months prior to or 12 months after a change in control), benefits increase to 12 months of base salary, 100% of the target bonus, 12 months of COBRA, and full acceleration of time-based equity awards.
- Contingency: Severance benefits are contingent upon the execution of a release of claims satisfactory to the Company.
Key Facts for Investor Verification
- Verify the impact of the CMO transition on the company's clinical development pipeline, particularly in inflammatory bowel disease.
- Review the dilution impact of the 75,000 options and 54,700 RSUs issued to Dr. Jones.
- Confirm the vesting schedule details: Options vest quarterly over 3 years; RSUs have an initial vesting tranche of 4,556 shares followed by 11 quarterly installments.
- Monitor future filings for any additional unregistered equity issuances or changes to the 2021 Inducement Plan.